These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 31646807

  • 1. High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis.
    Yildiz Y, Kabadayi G, Yigit S, Kucukzeybek Y, Alacacioglu A, Varol U, Taskaynatan H, Salman T, Oflazoglu U, Akyol M, Tarhan MO.
    J BUON; 2019; 24(4):1549-1554. PubMed ID: 31646807
    [Abstract] [Full Text] [Related]

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.
    J Exp Clin Cancer Res; 2017 May 08; 36(1):63. PubMed ID: 28482906
    [Abstract] [Full Text] [Related]

  • 3. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A.
    BMC Cancer; 2015 Jul 01; 15():492. PubMed ID: 26122176
    [Abstract] [Full Text] [Related]

  • 4. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, Shih IeM.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [Abstract] [Full Text] [Related]

  • 5. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M, Xie X, Ding Y.
    Oncol Rep; 2016 Mar 01; 35(3):1796-806. PubMed ID: 26750614
    [Abstract] [Full Text] [Related]

  • 6. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK.
    Int J Oncol; 2015 Feb 01; 46(2):607-18. PubMed ID: 25385265
    [Abstract] [Full Text] [Related]

  • 7. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K, Surówka J, Frąszczak K, Czerwonka A, Kaławaj K, Wawruszak A, Kotarski J, Wertel I.
    Tumour Biol; 2018 Oct 01; 40(10):1010428318804937. PubMed ID: 30319054
    [Abstract] [Full Text] [Related]

  • 8. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J, Kamieniak MM, Cazorla-Jiménez A, Muñoz-Repeto I, Borrego S, García-Donas J, Hernando S, Robles-Díaz L, García-Bueno JM, Ramón Y Cajal T, Hernández-Agudo E, Heredia Soto V, Márquez-Rodas I, Echarri MJ, Lacambra-Calvet C, Sáez R, Cusidó M, Redondo A, Paz-Ares L, Hardisson D, Mendiola M, Palacios J, Benítez J, García MJ.
    J Gynecol Oncol; 2016 Jan 01; 27(1):e7. PubMed ID: 26463438
    [Abstract] [Full Text] [Related]

  • 9. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK.
    Oncotarget; 2017 Mar 14; 8(11):17819-17832. PubMed ID: 28147318
    [Abstract] [Full Text] [Related]

  • 10. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M, Zannoni GF, Beltrame L, Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L, Vizzielli G, Scambia G, D'Incalci M, Romualdi C, Marchini S.
    Ann Oncol; 2016 Apr 14; 27(4):625-34. PubMed ID: 26782955
    [Abstract] [Full Text] [Related]

  • 11. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T, Li XP, Wang JL, Wang SJ, Wang Y, Sun XL, Cui H, Wei LH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug 14; 47(8):566-70. PubMed ID: 23141174
    [Abstract] [Full Text] [Related]

  • 12. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
    Mase S, Shinjo K, Totani H, Katsushima K, Arakawa A, Takahashi S, Lai HC, Lin RI, Chan MWY, Sugiura-Ogasawara M, Kondo Y.
    Cancer Sci; 2019 Mar 14; 110(3):1105-1116. PubMed ID: 30633424
    [Abstract] [Full Text] [Related]

  • 13. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
    Kang J, D'Andrea AD, Kozono D.
    J Natl Cancer Inst; 2012 May 02; 104(9):670-81. PubMed ID: 22505474
    [Abstract] [Full Text] [Related]

  • 14. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
    Smoter M, Bodnar L, Grala B, Stec R, Zieniuk K, Kozlowski W, Szczylik C.
    J Exp Clin Cancer Res; 2013 Apr 30; 32(1):25. PubMed ID: 23631819
    [Abstract] [Full Text] [Related]

  • 15. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q, Duan P, Li L, Miao Y.
    Tohoku J Exp Med; 2018 Apr 30; 244(4):291-296. PubMed ID: 29643276
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
    Abdelrahman AE, Fathy A, Elsebai EA, Nawar N, Etman WM.
    Ann Diagn Pathol; 2018 Aug 30; 35():27-37. PubMed ID: 30072015
    [Abstract] [Full Text] [Related]

  • 17. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
    Kakimoto S, Miyamoto M, Einama T, Matsuura H, Iwahashi H, Ishibashi H, Sakamoto T, Hada T, Takano M.
    Pathol Oncol Res; 2020 Oct 30; 26(4):2299-2306. PubMed ID: 32468249
    [Abstract] [Full Text] [Related]

  • 18. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN, Zeng LX, Li YH, Liu YZ, Wu JY, Li L, Wang Q.
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct 25; 52(10):687-696. PubMed ID: 29060967
    [Abstract] [Full Text] [Related]

  • 19. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
    Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B.
    Mol Cancer; 2015 Feb 18; 14():44. PubMed ID: 25889687
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.